En Carta Diagnostics

En Carta Diagnostics is a Paris-based diagnostic company pioneering novel testing solutions for infectious diseases. Its flagship program is a Lyme disease test that has received FDA Breakthrough Device Designation, indicating its potential to address a significant unmet clinical need. The company is in a pre-commercial stage, building a waitlist for its lead product while likely advancing its underlying technology platform. En Carta operates in the high-growth global infectious disease diagnostics market, targeting improved early detection and diagnosis.

Likely involves novel biomarker discovery and/or highly sensitive detection methodology for infectious diseases, focused on improving speed and accuracy of diagnosis. Specifics not publicly detailed.

Competes against established two-tiered serology tests and a growing number of novel diagnostic developers targeting Lyme disease. Differentiation will hinge on demonstrating superior clinical utility, speed, and accuracy to gain adoption in a conservative diagnostic market. Larger diagnostic firms pose a competitive threat but could also be potential acquirers.